Article Sidebar
Main Article Content
Berberine Alleviates 1-Methyl-3-Nitro-1-Nitrosoguanidine- Induced Chronic Atrophic Gastritis in Rats
Main Article Content
Abstract
Background/Aims: Berberine (BBR), an isoquinoline alkaloid derived from Berberis plants, exhibits anti-inflammatory, anti-cancer, and antioxidant properties. This study explored the role of BBR in chronic atrophic gastritis (CAG).
Materials and methods: The 1-methyl-3-nitro-1-nitrosoguanidine and an irregular diet were used to establish the CAG model. Chronic atrophic gastritis rats were administered BBR at different doses via gavage, and teprenone (TEP) served as the positive control drug. We monitored and measured changes in body weight and food intake, pepsin activity, and gastric acid levels in the rats. Hematoxylin and eosin staining was utilized to scan the pathological condition in the gastric mucosal tissue of rats, while enzyme-linked immunosorbent
assay was utilized to analyze alterations in serum inflammatory factors and hormone levels. Western blot was employed to evaluate protein expression. Additionally, 16S rRNA was conducted to assess changes in the intestinal flora of CAG rats.
Results: Berberine increased body weight and food intake, improved gastric atrophy, and enhanced pepsin activity and total acidity of gastric juice in CAG rats. BBR treatment led to decreased levels of inflammation factors and motilin, while gastrin and somatostatin levels were elevated in CAG rats. Additionally, BBR inhibited the NF-κB and MAPK pathway in these rats. Berberine treatment also regulated the composition and abundance of intestinal flora. These microbiome alterations suggest a possible role in modulating gut inflammation associated with CAG.
Conclusion: Berberine may alleviate CAG injury by reducing inflammation and regulating intestinal flora, which may be closely associated with the NF-κB and MAPK pathways.
Cite this article as: Wang L, Xie L. Berberine alleviates 1-methyl-3-nitro-1-nitrosoguanidine-induced chronic atrophic gastritis inrats. Turk J Gastroenterol. Published online April 7, 2025. doi 10.5152/tjg.2025.24065.
Article Details
References
1. Park YH, Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J Cancer Prev. 2015;20(1):25-40. [CrossRef]
2. Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012;44(1):74-94. [CrossRef]
3. Chen P, Cui Y, Fu QY, Lu YY, Fang JY, Chen XY. Positive relationship between p42.3 gene and inflammation in chronic non-atrophic gastritis. J Dig Dis. 2015;16(10):568-574. [CrossRef]
4. Luo C, Sun Z, Li Z, Zheng L, Zhu X. Notoginsenoside R1 (NGR1) attenuates chronic atrophic gastritis in rats. Med Sci Monit. 2019;25:1177-1186.
5. Engstrand L, Graham DY. Microbiome and gastric cancer. Dig Dis Sci. 2020;65(3):865-873. [CrossRef]
6. Jaroenlapnopparat A, Bhatia K, Coban S. Inflammation and gastric cancer. Diseases. 2022;10(3):35. [CrossRef]
7. Cicero AF, Baggioni A. Berberine and its role in chronic disease. Adv Exp Med Biol. 2016;928:27-45. [CrossRef]
8. Peng Z, Wangmu T, Li L, Han G, Huang D, Yi P. Combination of berberine and low glucose inhibits gastric cancer through the PP2A/GSK3β/MCL-1 signaling pathway. Eur J Pharmacol. 2022;922:174918. [CrossRef]
9. Luo Z, Li Z, Liang Z, et al. Berberine increases stromal production of Wnt molecules and activates Lgr5(+) stem cells to promote epithelial restitution in experimental colitis. BMC Biol. 2022;20(1):287. [CrossRef]
10. Habtemariam S. Berberine pharmacology and the gut microbiota: a hidden therapeutic link. Pharmacol Res. 2020;155:104722. [CrossRef]
11. Liu Q, Tang J, Chen S, et al. Berberine for gastric cancer prevention and treatment: multi-step actions on the Correa’s cascade underlie its therapeutic effects. Pharmacol Res. 2022;184:106440. [CrossRef]
12. Tong Y, Liu L, Wang R, et al. Berberine attenuates chronic atrophic gastritis induced by MNNG and its potential mechanism. Front Pharmacol. 2021;12:644638. [CrossRef]
13. Haftcheshmeh SM, Abedi M, Mashayekhi K, et al. Berberine as a natural modulator of inflammatory signaling pathways in the immune system: focus on NF-κB, JAK/STAT, and MAPK signaling pathways. Phytother Res. 2022;36(3):1216-1230. [CrossRef]
14. Zhao Y, Tian X, Liu G, Wang K, Xie Y, Qiu Y. Berberine protects myocardial cells against anoxia-reoxygenation injury via p38 MAPK-mediated NF-κB signaling pathways. Exp Ther Med. 2019;17(1):230-236. [CrossRef]
15. Zhao FQ, Zhao Y, Liu JY, Gou YJ, Yang YQ. [Effects of berberine on LPS /NF-κB and MAPK signaling pathways in PCOS model rats]. Zhongguo Ying Yong Sheng Li Xue Za Zhi Zhongguo Yingyong Shenglixue Zazhi Chin J Appl Physiol. 2022;38(2):181-186. [CrossRef]
16. Han Y, Guo S, Li Y, et al. Berberine ameliorate inflammation and apoptosis via modulating PI3K/AKT/NFκB and MAPK pathway on dry eye. Phytomedicine. 2023;121:155081. [CrossRef]
17. Gichner T, Velemínský J. Genetic effects of N-methyl-N’-nitro-N-nitrosoguanidine and its homologs. Mutat Res. 1982;99(2):129-242. [CrossRef]
18. Luo Y, Liang M, Yao W, et al. Functional role of lncRNA LOC101927497 in N-methyl-N’-nitro-N-nitrosoguanidine-induced malignantly transformed human gastric epithelial cells. Life Sci. 2018;193:93-103. [CrossRef]
19. Balendra V, Amoroso C, Galassi B, et al. High-salt diet exacerbates H. pylori infection and increases gastric cancer risks. J Pers Med. 2023;13(9):1325. [CrossRef]
20. Sipponen P, Maaroos HI. Chronic gastritis. Scand J Gastroenterol. 2015;50(6):657-667. [CrossRef]
21. Zhang J, Wang H. Morroniside protects against chronic atrophic gastritis in rat via inhibiting inflammation and apoptosis. Am J Transl Res. 2019;11(9):6016-6023.
22. Kubistová V. [Diagnosis of strabismus]. Cesk Oftalmol. 1987;43(1):9-11.
23. Yang GT, Zhao HY, Kong Y, Sun NN, Dong AQ. Correlation between serum vitamin B12 level and peripheral neuropathy in atrophic gastritis. World J Gastroenterol. 2018;24(12):1343-1352. [CrossRef]
24. Rehfeld JF. Gastrin and the moderate hypergastrinemias. Int J Mol Sci. 2021;22(13):6977. [CrossRef]
25. Al-Missri MZ, Jialal I. Physiology, Motilin. StatPearls [Internet]. 2022 Sep 26.
26. Curt AM, Popa Ilie IR, Cainap C, Balacescu O, Ghervan C. MicroRNAs and treatment with somatostatin analogs in gastroenteropancreatic neuroendocrine neoplasms: challenges in personalized medicine. J Gastrointestin Liver Dis. 2020;29(4):647-659. [CrossRef]
27. Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365-388. [CrossRef]
28. Chen J, Wang W, Zhang T, et al. Differential expression of phospholipase C epsilon 1 is associated with chronic atrophic gastritis and gastric cancer. PLoS One. 2012;7(10):e47563. [CrossRef]
29. Jeong M, Park JM, Han YM, et al. Dietary intervention of artemisia and green tea extracts to rejuvenate Helicobacter pylori-associated chronic atrophic gastritis and to prevent tumorigenesis. Helicobacter. 2016;21(1):40-59. [CrossRef]
30. Goldenring JR, Mills JC. Cellular plasticity, reprogramming, and regeneration: metaplasia in the stomach and beyond. Gastroenterology. 2022;162(2):415-430. [CrossRef]
31. Izadparast F, Riahi-Zajani B, Yarmohammadi F, Hayes AW, Karimi G. Protective effect of berberine against LPS-induced injury in the intestine: a review. Cell Cycle (Georget Tex). 2022;21(22):2365-2378. [CrossRef]
32. Barnabei L, Laplantine E, Mbongo W, Rieux-Laucat F, Weil R. NF-κB: at the borders of autoimmunity and inflammation. Front Immunol. 2021;12:716469. [CrossRef]
33. Jiang JY, Liu DJ, Liu MX. The protective effect of NF-κB signaling pathway inhibitor PDTC on mice with chronic atrophic gastritis. Scand J Gastroenterol. 2021;56(10):1131-1139. [CrossRef]
34. Gałgańska H, Jarmuszkiewicz W, Gałgański Ł. Carbon dioxide and MAPK signalling: towards therapy for inflammation. Cell Commun Signal. 2023;21(1):280. [CrossRef]
35. Park JI. MAPK-ERK pathway. Int J Mol Sci. 2023;24(11):9666. [CrossRef]
36. Zhang Q, Wang X, Cao S, et al. Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt signaling pathways. Biomed Pharmacother. 2020;128:110245. [CrossRef]
37. Park CH, Lee AR, Lee YR, Eun CS, Lee SK, Han DS. Evaluation of gastric microbiome and metagenomic function in patients with intestinal metaplasia using 16S rRNA gene sequencing. Helicobacter. 2019;24(1):e12547. [CrossRef]
38. Zhang S, Shi D, Li M, Li Y, Wang X, Li W. The relationship between gastric microbiota and gastric disease. Scand J Gastroenterol. 2019;54(4):391-396. [CrossRef]
39. Zhou P, Hao X, Liu Y, et al. Determination of the protective effects of Hua-Zhuo-Jie-Du in chronic atrophic gastritis by regulating intestinal microbiota and metabolites: combination of liquid chromatograph mass spectrometer metabolic profiling and 16S rRNA gene sequencing. Chin Med. 2021;16(1):37. [CrossRef]
40. Zhu HC, Jia XK, Fan Y, et al. Alisol B 23-acetate ameliorates azoxymethane/dextran sodium sulfate-induced male murine colitis-associated colorectal cancer via modulating the composition of gut microbiota and improving intestinal barrier. Front Cell Infect Microbiol. 2021;11:640225. [CrossRef]